Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. - Wikidata - awgldk - TriplyDB

Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.

Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.

http://www.wikidata.org/entity/Q43531369

about

Methotrexate for maintenance of remission in Crohn's disease Methotrexate for induction of remission in refractory Crohn's disease Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Management of Crohn's disease Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments Pharmacologic therapy for inflammatory bowel disease refractory to steroids Therapeutic drug monitoring in inflammatory bowel disease Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?Biologics in inflammatory bowel disease: what are the data?Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis Combination therapy for inflammatory bowel disease Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease.Use of methotrexate in inflammatory bowel disease in 2014: A User's Guide.Methotrexate for Inflammatory Bowel Diseases - New Developments The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model.Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.Managing refractory Crohn's disease: challenges and solutions Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease.Effectiveness and risk associated with infliximab alone and in combination with immunosuppressors for Crohn's disease: a systematic review and meta-analysis Combination therapy for the treatment of Crohn's disease.A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure.Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease.Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases.Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD Positioning therapy for Crohn's disease.Ulcerative colitis: current pharmacotherapy and future directions.The role and advances of immunomodulator therapy for inflammatory bowel disease.Management of inflammatory bowel disease in poor responders to infliximab.Anti-TNF therapeutics for the treatment of sarcoidosis.Treatment of IBD: where we are and where we are going.Conventional drug therapy for inflammatory bowel disease.Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease.Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events.Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases.

P2860

Q24194293-6A017CF9-A025-42BF-B291-567C3FC18A28 Q24194453-FE9D35B8-7282-464B-ADDD-0F316FDBA288 Q26745721-94F53964-37F7-454A-B41C-C0D68BA3A207 Q26777409-CB8D7C79-2C4A-4A6D-97C9-923F0D44116D Q26778252-ADAB6E6A-D40C-4923-9BB9-07B14C03562C Q26785537-5E2E5843-2FC6-4561-B497-3D9C01BA54AB Q26796415-CFE26C3E-C59F-4EFF-A278-154A881C17B6 Q26852729-2BD44FBA-A36E-4C2D-B215-CE738D0BCF75 Q28085725-63FDCFE3-29C1-4E72-A0AF-C2966F383CD8 Q30235581-645B8D9F-CD3F-47B0-AEB2-CC9A44462BCA Q30995889-FA9B8B34-018C-4DC3-A9AA-1529C66797E1 Q31017419-A192023A-836F-4939-BA19-E67ECF03A3DC Q33564492-9FB3164E-EB2D-4007-9681-B898125D5E57 Q33646452-8B7734D8-818B-4596-B386-DD7F7926C226 Q33654733-EE7E4522-F6A1-45D3-8EF7-D3DE20042DB1 Q34047653-774E93B7-3AFB-4AE4-9FE7-971F148CB0B9 Q34518393-02FA6576-3ADA-477D-9DD7-4C48E480CC3E Q35072606-D0E84B62-183F-4D82-BF7B-3F386209AF60 Q35193565-4A63946B-9BE5-4DAE-8DAD-E7A6EA4C9540 Q35460367-D8086F8B-C097-44B7-91A5-56DDAB40E977 Q35561386-8E92BB9D-3F17-42BB-AC7F-ED8723A20975 Q35679414-06E1DFBA-D1F6-4390-9E4D-C4C093691B13 Q35714202-ABC9F18D-45BC-48EF-BE41-2C575B45AE26 Q35973766-CD7A0DD6-EE3F-4063-B40E-1E0F5D0FF842 Q36150080-6C76F6E3-7C75-4F51-B648-6F4B45782445 Q36151324-80538A05-65A2-45BF-AC18-91CB49D36093 Q36209653-93D6F228-8B82-4C11-BDD7-8747E85E5471 Q36347059-1FB106DE-1696-40A5-9167-1F5A8B7799C3 Q36372720-30F66B4E-2ABD-4A7A-8437-F98C8EB67546 Q37613845-2F174F45-FCEF-48B5-90CD-0D26437A00F6 Q38200554-D4CE2320-BD69-4CA0-95B3-24FB0FD22F17 Q38217653-100B7DF1-339C-449D-B47F-829E746380AB Q38237701-A3F74ED0-1005-4CE0-81BA-A1331824A282 Q38254573-5E416DA3-52CB-4666-B5D8-572C4AC5D226 Q38271881-E29FAE3F-D58B-4277-B19B-5BB9EC79E695 Q38285619-FCE8C767-A624-4B49-A11D-6B2EF7EC6E2A Q38293796-AC0E6D9F-837D-4FE7-97BE-42274188BCB0 Q38323592-1E33C123-71E2-4F84-908F-06DEB537A9B7 Q38394816-73BDAA1F-2134-4514-9D94-4E9BBAFE18E0 Q38462602-4DE5E151-2E3C-491F-8DB9-2736602A94D8

P2860

Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.

http://www.wikidata.org/entity/Q43531369

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Methotrexate in combination wi ...... patients with Crohn's disease.

@en

Methotrexate in combination wi ...... patients with Crohn's disease.

@nl

type

label

Methotrexate in combination wi ...... patients with Crohn's disease.

@en

Methotrexate in combination wi ...... patients with Crohn's disease.

@nl

prefLabel

Methotrexate in combination wi ...... patients with Crohn's disease.

@en

Methotrexate in combination wi ...... patients with Crohn's disease.

@nl

P1433

Q43531369-65EFFE9B-EEF4-4DB1-B980-518BE3C45933

P1476

Q43531369-FA5B279E-4C5B-48D2-A9A4-02F89D9C04DD

P2093

Q43531369-0CABD6C6-D55E-4208-B33E-4411924D570A

Q43531369-14E54CEC-5A5A-4C0B-B804-1AC535AB356E

Q43531369-18706CC5-3F13-4ECC-8E27-8C291308B114

Q43531369-2B0C54D4-2D50-45E5-A176-51F384B68343

Q43531369-380448C0-DC7E-485E-B7FD-0CA08A878079

Q43531369-46D3C9AE-A964-4DBD-8D0D-21415501B0B7

Q43531369-4AA46B2A-71F6-4428-AFB4-34A462B16731

Q43531369-4FE09331-493E-4E28-A4D2-3C5B3971B203

Q43531369-6B235281-1823-4F21-B30A-564A1C0E5212

Q43531369-7F4C3BDF-25F8-42D6-BCBE-6199B2CD0295

P304

Q43531369-E1419C4F-829E-4FED-9B8F-78F7A5195343

P31

Q43531369-E96B66E3-2ED8-40A8-9B58-2C912CF18CCD

P356

Q43531369-D9922ED5-D574-499A-A71D-52D449EA251F

P407

Q43531369-2FB8C519-0A6A-42B3-9065-5D877DB4A6D6

P433

Q43531369-4C2043DA-0CB1-4E69-A06C-B3FCF573ED18

P478

Q43531369-D57AEA16-CB96-475A-9F2A-03D888DAEE68

P50

Q43531369-50AA72FD-6ABD-4716-862A-A95CA3C12CB2

Q43531369-C5E1B68E-84E8-4CC9-A393-DA075070FC09

P577

Q43531369-CD150AEA-ED67-4230-B2B3-63BEC6480B78

P698

Q43531369-5F2E13C8-D612-41C3-826B-A3500CC31C5D

P356

J.GASTRO.2013.11.024

P1433

Gastroenterology

P1476

Methotrexate in combination wi ...... patients with Crohn's disease.

@en

P2093

Alain Bitton

http://www.w3.org/2001/XMLSchema#string

Albert Cohen

http://www.w3.org/2001/XMLSchema#string

Allan Donner

http://www.w3.org/2001/XMLSchema#string

Charles N Bernstein

http://www.w3.org/2001/XMLSchema#string

Chrystian Dallaire

http://www.w3.org/2001/XMLSchema#string

Cindy J Wong

http://www.w3.org/2001/XMLSchema#string

Donald G Macintosh

http://www.w3.org/2001/XMLSchema#string

Frank Anderson

http://www.w3.org/2001/XMLSchema#string

Fred Saibil

http://www.w3.org/2001/XMLSchema#string

Gordon R Greenberg

http://www.w3.org/2001/XMLSchema#string

P304

681-688.e1

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2013.11.024

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

146

http://www.w3.org/2001/XMLSchema#string

P50

Richard N. Fedorak

Brian G. Feagan

P577

2013-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24269926

http://www.w3.org/2001/XMLSchema#string